# 68Ga-OPS202 Study for Diagnostic Imaging of GEP NET

> **NCT02162446** · PHASE1,PHASE2 · COMPLETED · sponsor: **Ipsen** · enrollment: 12 (actual)

## Conditions studied

- Gastroenteropancreatic Neuroendocrine Tumors

## Interventions

- **DRUG:** satoreotide trizoxetan

## Key facts

- **NCT ID:** NCT02162446
- **Lead sponsor:** Ipsen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06
- **Primary completion:** 2015-06
- **Final completion:** 2015-06
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2019-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02162446

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02162446, "68Ga-OPS202 Study for Diagnostic Imaging of GEP NET". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02162446. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*